Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.84 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.77 |
| ▸ | HTT | P42858 | 3/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | NPC1 | O15118 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.73 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.73 |
| ▸ | NAMPT | P43490 | 1/20 | 0.68 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | MPO | P05164 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15769552 | 0.92 | HTT (0.73) | NAAAALOX5HTTTSHRNPC1 | |
| SCHEMBL3155982 | 0.92 | NAAA (1.00) | NAAAALOX5HTTTSHRNPC1 | |
| SCHEMBL13385674 | 0.92 | NAAA (0.72) | NAAAALOX5HTTTSHRNPC1 | |
| SCHEMBL1543662 | 0.92 | NAAA (0.72) | NAAAALOX5HTTTSHRNPC1 | |
| SCHEMBL9662113 | 0.92 | NAAA (1.00) | NAAAALOX5HTTTSHRNPC1 | |
| SCHEMBL360518 | 0.92 | NAAA (1.00) | NAAAALOX5HTTTSHRNPC1 | |
| SCHEMBL13385681 | 0.92 | NAAA (0.72) | NAAAALOX5HTTTSHRNPC1 | |
| SCHEMBL359901 | 0.92 | NAAA (1.00) | NAAAALOX5HTTTSHRNPC1 | |
| SCHEMBL10705645 | 0.92 | NAAA (1.00) | NAAAALOX5HTTTSHRNPC1 | |
| SCHEMBL3289794 | 0.92 | NAAA (0.72) | NAAAALOX5HTTTSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2714924-B1 | HDAC Inhibitors for use in the treatment of Gaucher's disease, von Hippel-Lindau disease, phaeochromocytoma and paragangliomas. | LIXTE BIOTECHNOLOGY INC (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-2318005-B1 | NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | LIXTE BIOTECHNOLOGY INC (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2200439-B1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY INC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20160008336-A1 | HDAC INHIBITORS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-01-14 | — | — | US | disclosed |
| WO-2014137741-A1 | HDAC INHIBITORS FOR TREATING TRAUMATIC BRAIN INJURY | LIXTE BIOTECHNOLOGY, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140235649-A1 | USE OF PHOSPHATASE INHIBITORS OR HISTONE DEACETYLASE INHIBITORS TO TREAT DISEASES CHARACTERIZED BY LOSS OF PROTEIN FUNCTION | LIXTE BIOTECHNOLOGY, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8455688-B2 | HDAC inhibitors | LIXTE BIOTECHNOLOGY, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455688-B2 | HDAC inhibitors | LIXTE BIOTECHNOLOGY, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8329719-B2 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| WO-2012162535-A1 | USE OF PHOSPHATASE INHIBITORS OR HISTONE DEACETYLASE INHIBITORS TO TREAT DISEASES CHARACTERIZED BY LOSS OF PROTEIN FUNCTION | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-11-29 | — | — | WO | disclosed |
| US-8058268-B2 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| WO-2010014220-A1 | NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | LIXTE BIOTECHNOLOGY, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20090143445-A1 | HDAC Inhibitors | JOHN P. WHITE, ESQ | 2009-06-04 | — | — | US | disclosed |
| WO-2009045440-A1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY HOLDINGS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| US-5191003-A | Diamide compound, improved tire gripping, vibration insulation | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-03-02 | — | — | US | disclosed |
| EP-0470776-A1 | Rubber composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-02-12 | — | — | EP | disclosed |
| EP-0137074-A1 | Curable compositions containing epoxy resins and salicyloyl hydrocarbylamines and cured compositions thereof | THE DOW CHEMICAL COMPANY (US) | 1985-04-17 | — | — | EP | disclosed |
| US-4410681-A | Epoxy resins cured with salicyloyl hydrocarbylamines | THE DOW CHEMICAL COMPANY (US) | 1983-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | SNCA, NLN, HTT | NAAA 1015/4885ALOX5 2186/4885HTT 3/4885 |
| US-20160008336-A1 | HDAC INHIBITORS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY | HDAC5, HDAC1, HDAC4 | NAAA 729/4885ALOX5 4091/4885HTT 2208/4885 |
| US-20140235649-A1 | USE OF PHOSPHATASE INHIBITORS OR HISTONE DEACETYLASE INHIBITORS TO TREAT DISEASES CHARACTERIZED BY LOSS OF PROTEIN FUNCTION | HDAC1, PPP3CA, PPM1A | NAAA 1843/4885ALOX5 4680/4885HTT 558/4885 |
| US-20090143445-A1 | HDAC Inhibitors | HDAC3, HDAC7, HDAC4 | NAAA 2802/4885ALOX5 2923/4885HTT 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.